Laboratory of Molecular Carcinogenesis
The Laboratory of Molecular Carcinogenesis (LMC) studies (1) the regulation
and properties of enzymes of drug, carcinogen and xenobiotic metabolism;
(2) the molecular interaction of carcinogenic agents, primarily chemicals
and radiation with biological systems; (3) the genetic and environmental
factors in the metabolic activation and detoxification of xenobiotics such
as drugs and environmental chemicals. In addition, DNA repair, chromatin,
and cytochrome P450 structure, function and regulation are studied.
The Principal Investigators in our laboratory and their main areas of
research are:
-
Michael Bustin, Ph.D., Chromosomal Proteins and Chromatin
Structure
-
Fred K. Friedman, Ph.D., Structure, Function and
Regulation of Cytochrome P450
-
Harry V. Gelboin, Ph.D., Monoclonal Antibodies and
cDNA Expressed Human Cytochrome P450s to Study Drug and Carcinogen Metabolism
-
Tsuyoshi Kakefuda, M.D., Ph.D., Molecular Mechanism
of Mutation and Drug Resistance
-
Kenneth H. Kraemer, M.D., DNA Repair and Skin Cancer
Prevention
The Laboratory of Molecular Carcinogenesis periodically has openings for
postdoctoral fellows. Please direct inquiries to the appropriate Principal
Investigator.
-
(e-mail) gelboinh@intra.nci.nih.gov
-
(regular mail) NIH/NCI/LMC, Bldg 37/Rm 3E24, Bethesda, MD 20892
-
(tel) 301-496-6716
-
(fax) 301-496-8419
Last revised on Sept. 10, 1998 by Fred
K. Friedman